Share on StockTwits

Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson acquired 77,822 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $389,110.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Pacific Biosciences of California (NASDAQ:PACB) traded down 2.74% on Wednesday, hitting $4.97. 101,402 shares of the company’s stock traded hands. Pacific Biosciences of California has a 52-week low of $3.32 and a 52-week high of $8.20. The stock’s 50-day moving average is $5.24 and its 200-day moving average is $5.47. The company’s market cap is $351.0 million.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings data on Thursday, July 24th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the company posted ($0.33) earnings per share. Pacific Biosciences of California’s revenue was up 90.0% compared to the same quarter last year. Analysts expect that Pacific Biosciences of California will post $-1.07 EPS for the current fiscal year.

Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.